ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Endocrinology — Outside U.S. revenue [legacy] by Year
Endocrinology — Outside U.S. revenue ($M) [legacy] ($M)
Eli Lilly Endocrinology — Outside U.S. revenue [legacy]: $4,504M in FY2019, up 7.5% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2019
4,504
Period ended Dec 31, 2019
Change on a year earlier
+7.5%
4,191 in FY2018
History
4 years
Since FY2016
Sources
2
Documents cited below
Where the FY2019 figure comes from
Source: Form 10-K (filed 2020-02-19) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Endocrinology — Outside U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 4,504 | +7.5% | Form 10-K (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 4,191 | +12.9% | Form 10-K (filed 2020-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 3,712 | +14.2% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 3,251 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Endocrinology — Outside U.S. revenue [legacy] ($M), annual FY2016–FY2019 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta-endocrinology-nonus-legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.